Quick Answer
IDEAYA Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $112.83 million for the year ending 2025.
- IDEAYA Biosciences, Inc. showed an increase of +33.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from IDEAYA Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $24.87 million | Q3 2018: $21.48 million | Q1 2019: $35.30 million | Q2 2019: $88.12 million | Q3 2019: $38.85 million | Q1 2020: $35.46 million | Q2 2020: $147.54 million | Q3 2020: $81.24 million | Q1 2021: $136.75 million | Q2 2021: $90.43 million | Q3 2021: $108.43 million | Q1 2022: $55.29 million | Q2 2022: $49.11 million | Q3 2022: $101.95 million | Q1 2023: $67.24 million | Q2 2023: $102.84 million | Q3 2023: $151.85 million | Q1 2024: $108.35 million | Q2 2024: $183.05 million | Q3 2024: $400.28 million | Q1 2025: $130.00 million | Q2 2025: $114.65 million | Q3 2025: $298.93 million.
- Over the full 9 years of available data (2017 to 2025), IDEAYA Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,792.7%.
- Historical annual values: Fiscal year 2025: $112.83 million | Fiscal year 2024: $84.38 million | Fiscal year 2023: $157.02 million | Fiscal year 2022: $68.63 million | Fiscal year 2021: $92.05 million | Fiscal year 2020: $72.04 million | Fiscal year 2019: $34.07 million | Fiscal year 2018: $20.51 million | Fiscal year 2017: $5.96 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: